Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:09 PM
Ignite Modification Date:
2025-12-24 @ 5:09 PM
NCT ID:
NCT03847350
Eligibility Criteria:
Inclusion Criteria:
1. Male and female patient aged 19 and older
2. In patient diagnosed with essential hypertension,
* Patients who can be first treated with NEBILET®(Nebivolol) to lower high blood pressure
* In patients who are receiving other antihypertensive medications, those who can switch one of the antihypertensive agents to NEBILET®(Nebivolol) or use NEBILET®(Nebivolol) as an additional therapy (In case where one of other antihypertensive agents is switched to NEBILET®(Nebivolol), it is imperative that the dose of the previous medication should exhibit the same antihypertensive effect as NEBILET®(Nebivolol) 5 mg.)
3. Subjects who have signed the written informed consent form for their voluntary participation
Exclusion Criteria:
1. Patient with hypersensitivity to the NEBILET®(Nebivolol) substance
2. Patient with history of bronchospasm
3. Patient with history of bronchial asthma
4. Patient with metabolic acidosis
5. Patient with bradycardia(heart rate\< 60 bpm)
6. Patient with second and third degree atrioventricular block
7. Patient with acute heart failure, cardiogenic shock, or episodes of heart failure decompensation requiring i.v. inotropic therapy)
8. Patient with uncontrolled severe heart failure
9. Patient with hypotension (Systolic Blood Pressure \< 90mmHg)
10. Patient with severe peripheral circulatory disturbances
11. Patient with sick sinus syndrome including sino-atrial block
12. Patient with untreated pheochromocytoma
13. Patient with hepatic insufficiency
14. Patient with impaired liver function
15. Pregnant woman
16. Nursing mother
17. Patient with chronic heart failure who has severe renal insufficiency (serum creatinine ≥ 250 micro mol/L)
18. Patient with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption
19. Patient who has participated in other clinical trial within the last 3 months
Sex:
ALL
Minimum Age:
19 Years
Study:
NCT03847350
Study Brief:
Protocol Section:
NCT03847350